Strategic development support for novel therapeutics, from preclinical translation through IND readiness and clinical trials.
Strategic development support for novel therapeutics, from preclinical translation through IND readiness and clinical trials.
Biotech Founders · Academic Spinouts · Emerging Therapeutic Companies.
Supporting teams moving promising science toward IND-enabling development and early clinical translation.
One of the few Texas-based advisory groups built specifically for the academic-discovery-to-IND transition in oncology and cell/gene therapy. Our team merges scientific, translational, and regulatory insight into one cohesive solution.
Texas-first, nationally scalable. We anchor in the Houston/TMC ecosystem and extend through partnerships with CROs, accelerators, and translational networks.
Where others offer advice, we deliver execution.
Clarity, compliance, and collaboration at every stage of translation.
This framework advances every program toward FDA submission efficiently and confidently.
Use the CellGene Nexus 2026 Pre-IND Readiness Checklist to identify potential gaps across preclinical, translational, CMC, regulatory, and early clinical development.
Download the 2026 Readiness Checklist (pdf)
DownloadPreparing for an IND-enabling study, regulatory interaction, or early clinical development milestone? Tell us where your program stands and where you need support.
Not sure which service fits? Briefly describe your program stage and main challenge. We’ll recommend a fit or point you in the right direction.
Copyright © 2026 CellGene Nexus - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.